#1FDC FDC LIMITED Investor Presentation Q2FY23 www.fdcindia.com 1 FDC#2DISCLAIMER This report may contain certain statements that might be considered forward looking. These statements are subject to certain risk and uncertainties, since they are based on certain assumptions and expectations of future events. Actual results may differ materially from those expressed in the statement. The Company cannot guarantee that these assumptions and expectations are accurate and will be realised. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statement. FDC 2#3Platform to deliver sustainable value 1 Strong Domestic Business Multiple levers, high growth brands to anchor growth Zifi Category Creator in CEFIXIME - Electral Category creator & sustained leader in ORS ✓ Ophthalmology: legacy strength - 3rd highest in volumes ✓ Strong portfolio of functional foods & energy drinks 2 Best-in-class manufacturing facilities & regulatory track record ✓ Portfolio of high quality manufacturing facilities Revenues from multiple geographies, exporting to more than 50 countries. 3 Lan Strong Financials High Return on Capital Deployed in Business High financial capacity for growth investing 3 FDC#4Multiple Levers to drive growth Revenue Mix 25% Q2FY23 1(a) 303%95% (Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022) 4% 5% Domestic, 83% 7% Export, 17% Domestic Sales 26% 6% 56% 9% 29% Export Sales 102% 34% ■ Anti-Infectives ■ Gl ■ VMN ■ Derma ■ Ophthal ■Cardiac ■Gynaec. ■ Respiratory ■ Antiviral ■ Others 58% -7% -50% 235 294 274 347 369 31 48 96 48 75 Q2FY19 Q2FY20 Q2FY21 Q2FY22 Q2FY23 Q2FY19 Q2FY20 Q2FY21 Q2FY22 Q2FY23 Val Cr YOY Sales Growth % Val Cr YOY Sales Growth % Sales & Marketing (Source: Internal Data). 3,615 Medical representatives across 10 divisions marketing 130+ brands FDC#5Multiple Top Brands to anchor growth Brand Molecule Rank Rs. Crs MS % Electral Oral Electrolytes 1 350 74.2% Zifi Cefixime 1 320 24.7% Enerzal Energy Drinks 1 151 42.5% Vitcofol Folic acid + Cyanocobalamin + Nicotinamide 8 86 2.6% Zifi CV Cefixime + Clav. 1 75 46.2% Zathrin Azithromycin 4 59 4.4% Zocon Fluconazole 1 54 27.2% Zifi-O Cefixime + Ofloxacin 1 52 13.5% Simyl MCT Casein based + Soy based IMS 3 51 33.8% Amodep AT Amlodipine + Atenolol 5 39 6.3% Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022 1(a) FDC#6Electral - Category Creator & Consistent Leader in Oral Rehydration Salts Electral -Brand synomous with product category (Market Share) 74.4% 74.2% MAT Sep 22 MAT Sep 20 71.8% MAT Sep 21 Multiple SKUs to Driving Consistent Growth CHLENIGHTONSOLUTION ELECTRAL Apple Ronds To Drisk ORS GRAL RE-MERATION SALTS 1.P ELECTRAL ORS DO WHO. ORMA OPAL REHYDRATION SOLUTION ELECTRAL COS COMOTION SELFORT Na Gorrents 200 ORAL REHYDRATION SOLUTION ELECTRAL MEETS THE WHO RECOMMENTED CRE COMPOSITION VelderRY OPAL RE-MORATION SOLUTION ELECTRAL इलेक्ट्रास New Cones 200 ORAL REHYDRATION SALTS I.P ELECTRAL ORS BASED ON WH.O. FORMULA Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022 Brense lacier Net Contents 200 3 ml NOT FOR INJECTION DO In an otherwise fragmented market (Market Shares of Other Players) ■Market Share in MAT Sep 20 Market Share in MAT Sep 22 13.6% 12.9% 3.7% 2.9% 2.5% 1.4% 1.8% 1.7% WALYTE PROLYTE RELYTE-RTU Oral Rehydration Salts I.P. ELECTRAL O BASED ON INFORM सवाल ऑरेंज 21.80 u Oral Rehydration Salts I.P. ELECTRAL Electral is the first FDC Brand to enter Rs.350 Cr club and COSLYTE 1(b) FDC#7Zifi - Category Leader in CEFIXIME Zifi - Consistent Category Leader (Market Share) 23.9% 24.8% 24.7% MAT Sep 20 MAT Sep 21 MAT Sep 22 Multiple SKUs to Driving Consistent Growth QU 002BIZ CEFIXIME TABLETS IP 200 mg ZIFI 200 ज़िफी २०० FDC Prete Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022 R CEFIXIME ORAL SUSPENSION IP 50 mg/5 ml ZIFI 50 DRY SYRUP ज़िफी ५० ड्राइ सिरप WITH STERILE WATER FOR RECONSTITUTION 15g Powder furni sponsion 30 ml FDC In an otherwise fragmented market (Market Shares of Other Players) Market Share in MAT Sep 20 Market Share in MAT Sep 22 22.5% 23.1% 5.5% 5.7% 4.9% 5.7% 6.4% 5.5% TAXIM-O CEFOLAC OMNICEF-O MAHACEF 1(c) FDC#8Enerzal― Category Leader in Energy Drinks Enerzal-Consistent Category Leader (Market Share) 42.8% 40.1% 42.5% MAT Sep 20 MAT Sep 21 MAT Sep 22 ENERZAL WITH 5 VITAL FLECTROLYTES ENERZAL ENERZAL ENERZAL ENERZAL ENERZAL ENERZAL WITH 5 VITAL ELECTROLYTES ENERZAL ZERO SEPERTIEN ORN ENERZAL ENERZAL ENERZAL ENERZAL ENERZAL Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022 In an otherwise fragmented market (Market Shares of Other Players) Market Share in MAT Sep 20 Market Share in MAT Sep 22 26.6% 23.3% 16.7% 16.0% 14.1% 9.8% 3.3% 3.7% ORSL HEALTH OK ORSL PLUS ELECTROKIND-L 1(d) FDC#9Among top 20 Corporates in IPM in Prescriptions at Core Specialties in H1 (Apr-Sep YTD) % Growth Specialities FDC IPM % MS Rank Overall 51 47 5.6 13 GP-NON.MBBS 47 41 9.7 4 GP - MBBS 65 38 7.2 9 PEDIATRICIAN 76 72 5.7 16 ENT SPECIALIST 57 51 5.1 16 OPHTHALMOLOGIST 14 37 5.6 10 (Source: IQVIA-Medical Audit data Sep 2022 H1 (Apr-Sep) 1e) FDC#10Manufacturing Facilities Sinnar Food Plant Sinnar - Form Plant Goa (3 Facilities) Source: Internal Data Roha Waluj Baddi Dosage Form Tablet/Capsule Dry Syrup Liquid Oral Powder Ophthalmic Ear Drops Foods API Plant Food Plant Formulation Plant Baddi Goa 1/2 Goa 3 Sinnar Sinnar (Food) (Form) Waluj 2 (a) FDC#11TOP 10 Countries: Export Sale of APIs & Formulations Q2FY23 Export Formulation Sales - 58Crs 13% 2% 3% 3% 3% 3% 4% 4% 5% 5% Source: Internal Data 55% USA 21% New Zealand UK Chile Malaysia 4% Kathmandu 4% Ethiopia Myanmar PRESSREA 4% Tanzania Zimbabwe Others 5% Export API Sales - 17crs 7% 9% 7% 16% Germany Japan USA Saudi Arabia Turkey 14% Algeria South Korea Taiwan Australia 9% France ■Others 2 (b) FDC#12Quarterly Performance 45% 5% -6% 11% 13% 8% 6% 3% 332 312 445 396 341 337 493 447 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Sales (in Crs) YOY Sales Growth % 31% 28% 19% 26% 17% 20% 18% 9% 4.18 2.49 5.93 4.36 1.87 0.85 4.37 3.14 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 EPS in Rs -EBITDA % Source: Internal Data 3(a) FDC#13Quarterly Performance in crs. (except EPS) Q1FY23 Q1FY22 YoY % Revenue from operations 447 396 13% H1FY22 396 Other income 28 31 -8% Total Income 475 427 11% H1FY23 447 Operating Expenses 396 324 22% EBITDA 79 103 -23% Finance Cost 1.0 0.7 41% Depreciation 10 9 5% Profit before Tax 68 93 -26% H1FY22 4.36 Taxes 16 19 -17% Profit after Tax 54 76 -29% H1FY23 3.14 EPS 3.14 4.36 -28% Source: Internal Data Revenue from operations EPS 12% 27% 3(a) FDC#14For updates and company information, please visit our website i.e. www.fdcindia.com For specific queries, kindly email on [email protected] FDC#15THANK YOU FDC